| Principles and practice of pediatric oncology PA Pizzo, DG Poplack Lippincott Williams & Wilkins, 2015 | 1701 | 2015 |
| Identification of ALK as a major familial neuroblastoma predisposition gene YP Mossé, M Laudenslager, L Longo, KA Cole, A Wood, EF Attiyeh, ... Nature 455 (7215), 930-935, 2008 | 1637 | 2008 |
| The genetic landscape of high-risk neuroblastoma TJ Pugh, O Morozova, EF Attiyeh, S Asgharzadeh, JS Wei, D Auclair, ... Nature genetics 45 (3), 279-284, 2013 | 1174 | 2013 |
| Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study YP Mossé, MS Lim, SD Voss, K Wilner, K Ruffner, J Laliberte, D Rolland, ... The lancet oncology 14 (6), 472-480, 2013 | 779 | 2013 |
| Chromosome 1p and 11q deletions and outcome in neuroblastoma EF Attiyeh, WB London, YP Mossé, Q Wang, C Winter, D Khazi, ... New England Journal of Medicine 353 (21), 2243-2253, 2005 | 723 | 2005 |
| Copy number variation at 1q21. 1 associated with neuroblastoma SJ Diskin, C Hou, JT Glessner, EF Attiyeh, M Laudenslager, K Bosse, ... Nature 459 (7249), 987-991, 2009 | 440 | 2009 |
| ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma SC Bresler, DA Weiser, PJ Huwe, JH Park, K Krytska, H Ryles, ... Cancer cell 26 (5), 682-694, 2014 | 398 | 2014 |
| Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group Study YP Mossé, SD Voss, MS Lim, D Rolland, CG Minard, E Fox, P Adamson, ... Journal of Clinical Oncology 35 (28), 3215, 2017 | 375 | 2017 |
| A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene KA Cole, EF Attiyeh, YP Mosse, MJ Laquaglia, SJ Diskin, GM Brodeur, ... Molecular cancer research 6 (5), 735-742, 2008 | 355 | 2008 |
| Germline PHOX2B mutation in hereditary neuroblastoma YP Mosse, M Laudenslager, D Khazi, AJ Carlisle, CL Winter, E Rappaport, ... The American Journal of Human Genetics 75 (4), 727-730, 2004 | 351 | 2004 |
| Common variations in BARD1 influence susceptibility to high-risk neuroblastoma M Capasso, M Devoto, C Hou, S Asgharzadeh, JT Glessner, EF Attiyeh, ... Nature genetics 41 (6), 718-723, 2009 | 337 | 2009 |
| Chromosome 6p22 locus associated with clinically aggressive neuroblastoma JM Maris, YP Mosse, JP Bradfield, C Hou, S Monni, RH Scott, ... New England Journal of Medicine 358 (24), 2585-2593, 2008 | 314 | 2008 |
| Integrative genomics identifies LMO1 as a neuroblastoma oncogene K Wang, SJ Diskin, H Zhang, EF Attiyeh, C Winter, C Hou, RW Schnepp, ... Nature 469 (7329), 216-220, 2011 | 310 | 2011 |
| RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma KA Cole, J Huggins, M Laquaglia, CE Hulderman, MR Russell, K Bosse, ... Proceedings of the National Academy of Sciences 108 (8), 3336-3341, 2011 | 281 | 2011 |
| Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma SC Bresler, AC Wood, EA Haglund, J Courtright, LT Belcastro, ... Science translational medicine 3 (108), 108ra114-108ra114, 2011 | 268 | 2011 |
| Inhibition of ALK signaling for cancer therapy YP Mossé, A Wood, JM Maris Clinical Cancer Research 15 (18), 5609-5614, 2009 | 216 | 2009 |
| Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number Q Wang, S Diskin, E Rappaport, E Attiyeh, Y Mosse, D Shue, E Seiser, ... Cancer research 66 (12), 6050-6062, 2006 | 215 | 2006 |
| STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments SJ Diskin, T Eck, J Greshock, YP Mosse, T Naylor, CJ Stoeckert, ... Genome research 16 (9), 1149-1158, 2006 | 209 | 2006 |
| Retinoblastoma and neuroblastoma predisposition and surveillance J Kamihara, F Bourdeaut, WD Foulkes, JJ Molenaar, YP Mossé, ... Clinical Cancer Research 23 (13), e98-e106, 2017 | 201 | 2017 |
| Targeting ALK in neuroblastoma—preclinical and clinical advancements EL Carpenter, YP Mossé Nature reviews Clinical oncology 9 (7), 391-399, 2012 | 184 | 2012 |
